EASI score significantly lower for pediatric patients receiving vitamin D3 versus placebo with 1 percent hydrocortisone cream
FRIDAY, Nov. 6, 2020 (HealthDay News) — Vitamin D supplementation may aid clinical outcomes for pediatric patients with severe atopic dermatitis, according to a study published online Nov. 3 in Pharmacology Research & Perspectives.
Noha O. Mansour, Ph.D., from Mansoura University in Egypt, and colleagues randomly assigned 86 pediatric patients with severe atopic dermatitis to receive either vitamin D3 (1,600 IU/day) or placebo, plus baseline therapy of topical 1 percent hydrocortisone cream twice daily for 12 weeks.
The researchers found that the vitamin D3 group achieved a significantly higher level of 25 hydroxyvitamin D versus the control group at week 12. Compared with the placebo group, the mean Eczema Area and Severity Index (EASI) score was significantly lower in the treatment group. From baseline, the percent change in EASI score differed significantly between the two groups (supplementation versus placebo: 56.44 versus 42.09).
“Vitamin D supplementation could be an effective adjuvant treatment that improves the clinical outcomes in severe atopic dermatitis,” the authors write.
Copyright © 2020 HealthDay. All rights reserved.
